- CA$6.16m
- CA$7.26m
- CA$0.43m
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update
Brief: Kane Biotech Announces First Quarter 2025 Financial Results
Brief: Kane Biotech secures IRB approval to launch Dispersinb Acne trial
Brief: Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical For Revyve™ Antimicrobial Wound Gel
Brief: Kane Biotech Announces Second And Final Closing Of Private Placement Offering
Brief: Kane Biotech Announces Exclusive Distribution Agreement With XSONX
Brief: Kane Biotech Announces Distribution Agreement With Qatar Datamation Systems
Brief: Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve Antimicrobial Wound Gel
Brief: Kane Biotech Gets FDA Approval To Increase Dosage Allowance Of Revyve™ Antimicrobial Wound Gel
Brief: Kane Biotech Signs Worldwide License Agreement With Omni Bioceutical Innovations Inc.
Brief: Kane Biotech Makes First Commercial Sale Of Revyve™ Antimicrobial Wound Gel To ProgenaCare Global
Brief: Kane Biotech Signs Worldwide License Agreement With Montreal-Based I-MED Pharma
Brief: Kane Biotech Extends Exclusivity Period On Its Offer For Its Interest In STEM Animal Health
Brief: Dr. Robert Huizinga Elected To The Kane Biotech Board And Appointed Executive Chair
Brief: Kane Biotech Announces Amendment To Its Credit Facility
Brief: Kane Biotech Receives Offer For Its Interest In Stem Animal Health